Please select a hormone news story from our table of contents below:
Evolution assumes that extinction is forever. Maybe not. Henry Nicholls asks what it would take to bring the woolly mammoth back from the dead.
Q I cannot understand how experts can have such opposing views concerning the roles of testosterone and estrogen in prostate cancer. What is your opinion on the issue of male hormone replacement?
Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, announced that the New Drug Application (NDA) for the six-month formulation of Trelstar (triptorelin pamoate) has been accepted for filing by the United States (US) Food and Drug Administration (FDA). Trelstar is a luteinizing hormone ...
Watson Pharmaceuticals, a specialty pharmaceutical company, has announced that its new drug application for a six-month formulation of Trelstar, a luteinizing hormone releasing hormone agonist, has been accepted for filing by the FDA.
Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced that its New Drug Application for a 6-month formulation of TRELSTAR® , a luteinizing hormone releasing hormone agonist, has been accepted for filing by the U.S.
Debiopharm Group , a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, today announced that the New Drug Application for the 6 month formulation of Trelstar® has been accepted for filing by the United States Food and Drug Administration .
Melatonin is typically taken half an hour before bedtime for the first 4 days after traveling. For ordinary insomnia, melatonin is usually taken about 30 minutes to 1 hour before bedtime.
AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, recently announced that it has signed a definitive agreement to sell to Cowen Healthcare Royalty Partners, L.P.
After selling a building, a marketed product and a subsidiary during the past year, AEterna Zentaris Inc. continued its asset monetization strategy by selling its Cetrotide (cetrorelix) royalties to Cowen Healthcare Royalty Partners LP in exchange for $52.5 million.
AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it has signed a definitive agreement to sell to Cowen Healthcare Royalty Partners, L.P. its rights to royalties on future sales of Cetrotide covered by its license agreement with Merck Serono.
biopharmaceutical pharmaceutical